Using group testing in a two-phase epidemiologic design to identify the effects of a large number of antibody reactions on disease risk.
BMC Med Res Methodol
; 22(1): 324, 2022 Dec 16.
Article
em En
| MEDLINE
| ID: mdl-36526967
ABSTRACT
BACKGROUND:
The role of immunological responses to exposed bacteria on disease incidence is increasingly under investigation. With many bacterial species, and many potential antibody reactions to a particular species, the large number of assays required for this type of discovery can make it prohibitively expensive. We propose a two-phase group testing design to more efficiently screen numerous antibody effects in a case-control setting.METHODS:
Phase 1 uses group testing to select antibodies that are differentially expressed between cases and controls. The selected antibodies go on to Phase 2 individual testing.RESULTS:
We evaluate the two-phase group testing design through simulations and example data and find that it substantially reduces the number of assays required relative to standard case-control and group testing designs, while maintaining similar statistical properties.CONCLUSION:
The proposed two-phase group testing design can dramatically reduce the number of assays required, while providing comparable results to a case-control design.
Texto completo:
1
Base de dados:
MEDLINE
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article